Abstract:Objective To explore effect of γ-secretase inhibitor on mouse model of bleomycin-induced pulmonary fibrosis. Methods 15 mice were randomly divided into 3 groups: control group, model group and DAPT group (n?=?5). Pulmonary fibrosis model was established by intratracheal instillation of bleomycin (5?mg/kg). Mice in control group was treated by intratracheal instillation of saline (1.25?ml/kg). Mice in DAPT group were administered with DAPT solution by gavage 5?mg/(kg?d) every two days for 28 days. Mice were sacrificed at 28th day and the pathological changes of the lung tissues were observed by HE staining. The levels of NOTCH1, IL-17 and α-SMA mRNA in lung tissues was tested by real-time quantitative qRT-PCR. The serum level of NOTCH1 and IL-17 was detected by ELISA. The proportion of splenic Th17 cells in each group was detected by flow cytometry. Results HE staining result showed the mice in model group experienced the most severe pulmonary fibrosis and alveolar inflammation compared with control group (P?0.05), which was reversed with treatment of DAPT (P?0.05). RT-PCR results showed that the levels of NOTCH1, IL-17 and a-SMA in the model group were higher than those in the control group (P?0.01), which was normalized in DAPT group. Levels of NOTCH1 was positively correlated with IL-17 (P?0.01), suggesting that NOTCH signaling pathway was activated in the process of pulmonary fibrosis. ELISA result showed the serum level of NOTCH1 and IL-17 in DAPT group was significantly reduced compared with the model group (P?0.05). Th17 cells in PBMC of mice increased in model group compared with control group, while that in DAPT group decreased significantly. Conclusions DAPT reduces pulmonary fibrosis through inhibiting the differentiation of Th17 cell.